Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map

Derm News: 2006(22)

Cost Effectiveness of Management of Mild-to-Moderate Atopic Dermatitis with 1% Pimecrolimus Cream in Children and Adolescents 2-17 Years of Age

American Journal of Clinical Dermatology
Charles N Ellis; Kristijan H Kahler; Jens Grueger; Jane Chang


Atopic dermatitis (AD) has the potential to cause a long-term economic impact on patients, their families, and the healthcare system.


To determine if 1% pimecrolimus cream is cost-effective in treating mild-to-moderate AD in patients 2-17 years of age.


Data on the efficacy of AD management with 1% pimecrolimus cream (Elidel(R), Novartis Pharma GmbH, Wehr, Germany) were obtained from a 12-month, randomized, double-blind, multinational, controlled clinical trial comparing pimecrolimus and conventional therapy. Markov modeling was used for the economic model, based on: (i) Investigator's Global Assessment scores assessed at each visit during the clinical trial; (ii) estimated costs for medication and physician visits for each level of disease severity; and (iii) utility values for each level of disease severity. The perspective was that of a third-party payer.


In 2004 US dollars, the incremental cost-effectiveness of 1% pimecrolimus cream was $US38 231 per quality-adjusted life year (QALY) gained compared with conventional therapy. Sensitivity analyses showed a range of $US27 299 to $US63 457 per QALY gained.


With an incremental cost-effectiveness ratio of <$US50 000 per QALY gained, 1% pimecrolimus cream offers a cost-effective therapeutic option in the management of AD.

    Back to Current Volume:   Dermatology News 2006

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter© and its founding editor Dr. Stuart Maddin.